The US government has cancelled its $877.5 million contract with VaxGen, Inc. for a new anthrax vaccine, likely delaying by at least three years the creation of a recombinant-based stockpile sufficient to immunize 25 million Americans.The Department of Health and Human Services (HHS) said this week that it had terminated its two-year-old contract with VaxGen, a small San Francisco area biotech company, because the vaccine was unstable, breaking down too quickly over time for the government to allow it to be tested in clinical trials. VaxGen was two years behind in the delivery schedule for the vaccine, which called for the first third of the supply to be delivered by the end of this year, according to Marc Wolfson, an HHS spokesman. Because the company did not deliver any vaccine, it never received any payment. "The $877.5 million is still in the US Treasury," Wolfson told The Scientist....
The ScientistEmergent BiosolutionsAveciagrantstwo major firstname.lastname@example.orgThe Scientisthttp://www.the-scientist.com/article/display/23168http://www.b2i.us/profiles/investor/NewsPDF.asp?b=923&ID=18263&m=rlhttp://www.emergentbiosolutions.com/pdf/121406-completedDeliveryof3MofAVAtoHHS.pdfhttp://www.avecia.comThe Scientisthttp://www.the-scientist.com/news/20030701/01The Scientisthttp://www.the-scientist.com/article/display/20009
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!